I am proud to have joined the NORD board earlier this year. And I am particularly proud of the petition recently submitted to the FDA.
NORD's petition raises the collective voice of rare disorders regarding regulatory issues. Rare disorders present opportunities and challenges for the FDA. NORD's request for a statement of policy will provide guidance for this shared concern. Rare diseases have come of age and this policy will be critical if we are to develop treatments for over 30 million Americans whose lives are impacted by over 7,000 rare diseases.